You are here » Home » Companies » Company Overview » RPG Life Sciences Ltd

RPG Life Sciences Ltd.

BSE: 532983 Sector: Health care
NSE: RPGLIFE ISIN Code: INE105J01010
BSE LIVE 15:50 | 17 Nov 381.10 0.65
(0.17%)
OPEN

388.35

HIGH

388.35

LOW

380.00

NSE 15:47 | 17 Nov 383.15 -1.30
(-0.34%)
OPEN

385.00

HIGH

387.30

LOW

379.65

OPEN 388.35
PREVIOUS CLOSE 380.45
VOLUME 2946
52-Week high 537.50
52-Week low 294.00
P/E 89.04
Mkt Cap.(Rs cr) 630
Buy Price 381.10
Buy Qty 40.00
Sell Price 0.00
Sell Qty 0.00
OPEN 388.35
CLOSE 380.45
VOLUME 2946
52-Week high 537.50
52-Week low 294.00
P/E 89.04
Mkt Cap.(Rs cr) 630
Buy Price 381.10
Buy Qty 40.00
Sell Price 0.00
Sell Qty 0.00

RPG Life Sciences Ltd. (RPGLIFE) - Company History

RPG Life Sciences Ltd is engaged in the development, manufacture, and marketing of bulk drugs and formulations primarily in India. The company provides active pharmaceutical ingredients and generic formulations, as well as medications for critical and chronic ailments. They also manufacture life saving drugs using biotechnology. The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.